Mimi Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Correspondence to letter to the editor on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Correspondence to letter to the editor on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Journal: Clinical and molecular hepatology

Published: January 20, 2026

Key challenges in cost-effectiveness analyses of emerging MASLD therapies: adherence, adverse events, cardiometabolic benefits, and age-related uncertainty: Correspondence to editorial on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Key challenges in cost-effectiveness analyses of emerging MASLD therapies: adherence, adverse events, cardiometabolic benefits, and age-related uncertainty: Correspondence to editorial on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Journal: Clinical and molecular hepatology

Published: January 13, 2026

Rule-Out Cutoff of Two-Dimensional Shear Wave Elastography for Significant Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Systematic Review, Meta-Analysis, and External Validation.

Rule-Out Cutoff of Two-Dimensional Shear Wave Elastography for Significant Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Systematic Review, Meta-Analysis, and External Validation.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: September 17, 2025

Treatment nonresponders in lupus nephritis characteristically exhibit persistent type I interferon signalling in monocytes: a longitudinal single-cell transcriptomic analysis.

Treatment nonresponders in lupus nephritis characteristically exhibit persistent type I interferon signalling in monocytes: a longitudinal single-cell transcriptomic analysis.

Journal: Annals of the rheumatic diseases

Published: August 06, 2025

Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease.

Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease.

Journal: Clinical and molecular hepatology

Published: July 18, 2025

Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests.

Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests.

Journal: Scientific reports

Published: February 06, 2025

Tracking clonal dynamics of CD8 T cells and immune dysregulation in progression of systemic lupus erythematosus with nephritis.

Tracking clonal dynamics of CD8 T cells and immune dysregulation in progression of systemic lupus erythematosus with nephritis.

Journal: Experimental & molecular medicine

Published: January 14, 2025

Limited use of FIB-4 index in patients under 65 years of age with type 2 diabetes mellitus.

Limited use of FIB-4 index in patients under 65 years of age with type 2 diabetes mellitus.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 27, 2024

Distinct characteristics of MetALD (metabolic dysfunction-associated steatotic liver disease with greater alcohol consumption) in the general population.

Distinct characteristics of MetALD (metabolic dysfunction-associated steatotic liver disease with greater alcohol consumption) in the general population.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 14, 2024

Perirenal fat thickness is an independent predictor for metabolic syndrome in steatotic liver disease.

Perirenal fat thickness is an independent predictor for metabolic syndrome in steatotic liver disease.

Journal: Scientific reports

Published: July 19, 2024

Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up.

Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up.

Journal: Scientific reports

Published: July 03, 2024

Diagnostic performances of Fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction-associated steatotic liver disease in Asian primary care clinics.

Diagnostic performances of Fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction-associated steatotic liver disease in Asian primary care clinics.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 15, 2024

Showing 1-12 of 65

Last Updated: 09/26/2026